Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Discov. 2020 Nov 6;11(2):362–383. doi: 10.1158/2159-8290.CD-20-0455

Figure 1.

Figure 1.

Generation of tumorigenic organoids. A, OncoPrint showing selected genetic alterations and co-occurrence of the indicated abnormalities in human HGSC (TCGA, Firehose Legacy). B, Schematic showing approach for generating tumorigenic organoids from parental Tp53f/f;Brca1f/f or Tp53f/f FTE organoids. C, Representative bright field images and immunofluorescence staining of organoids after 7 days in culture. Scale bars: 20 μm. D, Exposed abdomens (right panels) and dissected genital tracts (right panels) of mice bearing organoid-derived tumors of the indicated genotypes; asterisks indicate large metastatic deposits. E, K–M curves of mice following orthotopic injection of 2X106 organoid cells of the indicated genotypes, n=6/group. F, H&E-stained sections and immunohistochemical analysis for the HGSC markers PAX8, CK7 (Cytokeratin 7), Ki67, and WT1 (Wilms’ Tumor 1) in representative sections from the indicated ovarian tumors. Scale bars: 50 μm. See also Supplementary Figs. S1 and S2.